obesity

Page 5 of 12

The last time there was this much hype over a new drug was for Viagra, which was approved in 1998. Yet hurdles remain, when it comes to the ability of patients to access weight loss and anti-diabetes injectables like Zepbound and Wegovy: These drugs cost a lot, insurance coverage is spotty, and patients may need to take them indefinitely to avoid regaining weight.
Health

Weight-loss injectables like Zepbound are making as big of a splash as Viagra, if not bigger. What you need to know about the ‘miracle drugs’

By Emma Court, Madison Muller and Bloomberg
January 31, 2024
Novo Nordisk hits $500B market value, climbing closer to the $1T club as it forecasts Wegovy and Ozempic will juice another 29% jump in profits this year
Retail

Novo Nordisk hits $500B market value, climbing closer to the $1T club as it forecasts Wegovy and Ozempic will juice another 29% jump in profits this year

By
January 31, 2024
North Carolina drops coverage for Wegovy and Ozempic, with implications for anti-obesity drug market projected to hit $100B by 2030
Health

North Carolina drops coverage for Wegovy and Ozempic, with implications for anti-obesity drug market projected to hit $100B by 2030

By Simone Foxman, Madison Muller and Bloomberg
January 27, 2024
Millions of older Americans can’t get weight loss drugs like Wegovy because Medicare won’t pay for them
Health

Millions of older Americans can’t get weight loss drugs like Wegovy because Medicare won’t pay for them

By Amanda Seitz and The Associated Press
December 28, 2023
Roughly half of the U.S. population has diabetes or its predecessor. It makes us a nation of sick people, experts say—driving up the country’s health care infrastructure and staffing needs and the cost of health care, and harming the economy in a way never seen before in U.S. history.
Health

Nearly half of the U.S. population has diabetes or prediabetes—and many have no clue. Are you among them?

By
December 23, 2023
doctor's scale.
Health

Severe obesity increasing among young American children, new study confirms

By Mike Stobbe and The Associated Press
December 18, 2023
Roche pushes to catch up to Novo Nordisk’s Wegovy with $3.1bn deal for obesity drugmaker Carmot
Finance

Roche pushes to catch up to Novo Nordisk’s Wegovy with $3.1bn deal for obesity drugmaker Carmot

By Paula Doenecke and Bloomberg
December 4, 2023
Novo Nordisk responds to U.S. rival Eli Lilly by announcing new $2.3 billion investment in France to keep up with soaring demand for weight-loss drugs
Health

Novo Nordisk responds to U.S. rival Eli Lilly by announcing new $2.3 billion investment in France to keep up with soaring demand for weight-loss drugs

By
November 23, 2023
Obesity drugs in Ozempic, Wegovy and Mounjaro are trimming back the Thanksgiving ‘food orgy’
Health

Obesity drugs in Ozempic, Wegovy and Mounjaro are trimming back the Thanksgiving ‘food orgy’

By Jonel Aleccia and The Associated Press
November 20, 2023
So many Americans are using Novo Nordisk’s blockbuster weight loss-aiding Ozempic that Germany may ban exports of the drug
Retail

So many Americans are using Novo Nordisk’s blockbuster weight loss-aiding Ozempic that Germany may ban exports of the drug

By
November 16, 2023
Wegovy, an injectable prescription weight-loss medicine.
Health

A ‘game-changing’ study backs Wegovy use to cut heart attacks and strokes: ‘This is not just about weight and appearance’

By Madison Muller, Naomi Kresge and Bloomberg
November 11, 2023
Novo Nordisk faces first real test as Eli Lilly wins approval for a weight loss-aiding drug—and it’s nearly $300 cheaper than Wegovy
Retail

Novo Nordisk faces first real test as Eli Lilly wins approval for a weight loss-aiding drug—and it’s nearly $300 cheaper than Wegovy

By
November 9, 2023
Medications aren’t required to be tested in people with obesity. Here’s why that’s a problem
Health

Medications aren’t required to be tested in people with obesity. Here’s why that’s a problem

By Jonel Aleccia and The Associated Press
November 7, 2023
Europe’s most valuable drugmaker Novo Nordisk is threatening the EU with a shift to the U.S.
Health

Europe’s most valuable drugmaker Novo Nordisk is threatening the EU with a shift to the U.S.

By
November 6, 2023
Brands like Walmart and Nestle are right to worry about Wegovy. Novo Nordisk sold $900m of the weight loss drug last quarter—and 95% was in the U.S.
Health

Brands like Walmart and Nestle are right to worry about Wegovy. Novo Nordisk sold $900m of the weight loss drug last quarter—and 95% was in the U.S.

By
November 2, 2023

Most Popular